

This is not an ADB material. The views expressed in this document are the views of the author/s and/or their organizations and do not necessarily reflect the views or policies of the Asian Development Bank, or its Board of Governors, or the governments they represent. ADB does not guarantee the accuracy and/or completeness of the material's contents, and accepts no responsibility for any direct or indirect consequence of their use or reliance, whether wholly or partially. Please feel free to contact the authors directly should you have queries.


# Driving R&D Towards Global Public Health and Health Equity: RIGHT Foundation's Approach

Hoon Sang Lee, MD, MPH, PhD  
CSO, RIGHT Foundation

9 July 2025

## RIGHT foundation: Korea's first non-profit organization dedicated to funding global health R&D

- Established in 2018 with the intent to engage Korean life science partners to develop and make available critical health technologies as global public good
- Public private partnership with the Korean Ministry of Health and Welfare (MOHW), Bill & Melinda Gates Foundation and Korean life science industry
- Leverages the Korean Ministry of Health and Welfare's Official Development Assistance



Gates Foundation



# Our Vision, Mission & Objectives

## Vision:

A world where infectious diseases pose no threat to any community

**Mission:** Alleviate the burden of infectious diseases that disproportionately affect the people in low- and middle-income countries (LMICs)

Strategic Objectives & Funding Programs	PRODUCT DEVELOPMENT AWARD	EVIDENCE GENERATION AWARD	TRAINING AWARD
	Develop essential health technologies as global public goods (e.g. public procurement, global access, technology transfer)	<ul style="list-style-type: none"> <li>Fill critical knowledge gaps to further the impact of product development (e.g. support licensure, policy development or public procurement)</li> </ul>	Train work force in manufacturing essential health technologies (e.g. regional-level self-sufficiency in vaccine manufacturing)
Core Value	<p style="text-align: center;"><b>COLLABORATION</b></p> <ul style="list-style-type: none"> <li>Foster an exchange of knowledge and skills (i.e. co-develop)</li> <li>Contribute Korea's strengths in engineering, process optimization, manufacturing</li> </ul>		

## RIGHT's Funding Programs

	Product Development Award	Evidence Generation Award	Training Award
<b>Objectives</b>	<ul style="list-style-type: none"> <li>Develop essential medical countermeasures as global public goods</li> </ul>	<ul style="list-style-type: none"> <li>Fill critical knowledge gaps to further the impact of product development (e.g. support licensure, policy development or public procurement)</li> </ul>	<ul style="list-style-type: none"> <li>Train work force in manufacturing essential medical countermeasures</li> </ul>
<b>Development Stage</b>	<ul style="list-style-type: none"> <li>From pre-clinical development at/near IND-enabling studies throughout clinical development to regulatory approval and/or WHO prequalification</li> <li>Access Enabling Research</li> <li>Technology Transfer</li> </ul>	<ul style="list-style-type: none"> <li>n/a</li> </ul>	<ul style="list-style-type: none"> <li>Basics for biopharmaceuticals and bioprocessing</li> <li>Vaccine manufacturing bioprocessing</li> <li>Regulatory process for biopharmaceuticals</li> </ul>
<b>Product Types</b>	vaccines, therapeutics/biologics, diagnostics		vaccines
<b>Requirements</b>	<ul style="list-style-type: none"> <li>At least one Korean partner,</li> <li>50% co-funding if the project team consists of a commercial partner</li> </ul>	<ul style="list-style-type: none"> <li>Local institutions from the countries that the proposed activities focus on</li> </ul>	<ul style="list-style-type: none"> <li>Individuals from LMICs holding positions related to vaccine manufacturing</li> </ul>
<b>Funding Amount &amp; Duration</b>	<ul style="list-style-type: none"> <li>Up to 4 billion KRW/project (approximately 3.4M USD) for 3 years</li> </ul>	<ul style="list-style-type: none"> <li>Up to 200 million KRW/ project (approximately 165,000 USD, 1 yr)</li> </ul>	<ul style="list-style-type: none"> <li>3-week on-line and 5-week hands-on training in Korea including travel expenses and accommodation</li> </ul>
<b>Investment Criteria</b>	<ol style="list-style-type: none"> <li>Infectious diseases with a disproportionate burden in LMICs</li> <li>Unmet medical needs for new or improved health products</li> <li>Insufficient commercial incentives to drive R&amp;D innovation</li> <li>Opportunity to contribute Korea's strengths in R&amp;D</li> </ol>		

# Driving R&D to serve global and regional public health : what it means and what it does not mean

## Key Considerations:


- Design with **global access** in mind from the start (e.g. context, target use-case, product characteristics, end-user requirements)
- Plan for integration into the **local public health system**
- Develop **market access strategies** early (private AND public market)
- Engage the **key stakeholders** early (e.g. end-users, local governments, regulatory authorities, global procuring agencies)
- Seeks innovation outside the “first-in-class” paradigm to achieve global access (ie. optimize manufacturing process, improve thermostability, improve ease of operation/implementation)
- Global health R&D should NOT mean charity




Baboucarr Sarr, community health nurse and midwife, talking to a young mother at an outreach immunisation session in Nioro-Jataba, The Gambia. Credit: Gavi/2018/Guido Dingemans

# Funding committed across award and product type


## By Award Type



## By Product Type



# Funding committed across disease type



1) **Pneumonia**: Meningitis + Neonatal Sepsis; 2) **EDD**: Enteric and Diarrheal diseases + Cholera + Hep A + Rotavirus + Typhoid; 3) **NTD**: Neglected Tropical Diseases, Chikungunya + Dengue + Leishmaniasis + Schistosomiasis + Onchocerciasis; 4) **Combined**: Hexa, Penta, Measles-Rubella, Multiple infectious diseases; 5) **STIs/AMR**: Sexually transmitted infections + antimicrobial resistance; 6) **Pandemic potential**, COVID19 + Influenza; 7) **GAS**: Group A Streptococcus; 8) **Others**: 4 EGAs and 1 TA not specific to diseases; 9) **SFTS**: Severe fever with thrombocytopenia syndrome


# Currently Active Grants: RiGHT aims for an impact-driven, risk-balanced portfolio

**Vaccines**  
Total 8  
25.3 million  
USD

**Therapeutics**  
Total 5  
12.9 million  
USD

**Diagnostics**  
Total 9  
19.0 million  
USD

**Total 22 grants**  
**Total Committed Funding by RiGHT: 57.2 million USD**  
**Total Project Costs: 156.0 million USD**



\*POCT: Point-of-Care molecular diagnostic test

# What does success look like for RIGHT?



STANDARD G6PD



- First quantitative rapid diagnostic test to detect Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Policy recommendation by Brazil to adopt single-dose tafenoquine and STANDARD G6PD Test for the treatment of relapsing *P.vivax* malaria.
- Introduced in Cambodia, Laos, and Vietnam for routine test use with primaquine (the standard treatment for *P. vivax*).
- Currently, registered in 18 malaria endemic countries

<https://medaccess.org/our-agreements/agreements/g6pd-testing/>

Impact to date	<b>9,000</b>	<b>20,300</b>	<b>\$369,000</b>
By the end of 2023:	<i>additional people on any treatment</i>	<i>malaria relapses averted</i>	<i>savings for procurers</i>

# What does success look like for RIGHT? miLabMAL Platform

## Microscopic Test



VS

## miLab



<b>SLOW</b> 20-90 min.		<b>FAST</b> 15-25 min.
<b>TEDIOUS</b> 8 steps		<b>SIMPLE</b> 3 steps
<b>15 types of</b> material & reagents		<b>ONE</b> Cartridge
Sink Water supply Sewage Liquid Waste Ventilation		<b>NO</b> Infrastructure

- an AI-powered malaria diagnostic platform with a fully automated process from sample preparation (including smearing and staining) to data analysis
- Fully automated sample preparation, including smearing and staining
- Licensure by CE/IVDR, TFDA, FDA & MHRA
- Successful field evaluation study by National Institute of Public Health (INSP) of Côte d'Ivoire
- Agreement with the Government of Benin for large-scale public procurement to deliver at least 219 miLab™ units over three years
- Further application potential for diagnosis of cervical cancer being explored

# RIGHT project partners

## International

TOTAL

**22**

Countries

Of which

LMIC

**12**

Countries

TOTAL

**46**

Institutions

Of which

LMIC

**20**

Institutions

**Korean**

TOTAL

**64**

Institutions

# Acknowledgement



## Gates Foundation

<b>Full Partner</b>	 eu <b>bi</b> ologics	 SD BIOSENSOR	 SK bioscience	 LG Chem
<b>Associate Partner</b>	 BIONEER <i>Innovation · Value · Discovery</i>	 noul Beyond Diagnostics	 QuadMedicine SHAPE A WHOLE NEW WORLD	

